Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
May 09, 2024
As many countries around the world prepare to celebrate Mothers’ Day weekend, including in the United States, care is at the top of many people’s minds. This theme resonates from intimate household spaces to the broad corridors of global policy. The G20 is one global policy space where, each year, i...
Blog Post
April 17, 2024
In the wake of COVID and amidst global crises, care has increasingly become recognized as a global issue critical for sustainable development and gender equality. Yet, there are still massive gaps in care policies, services, and financing, and there is much more work that needs to happen to ensure u...
Blog Post
March 27, 2024
Today marks a significant milestone as the Bill & Melinda Gates Foundation (BMGF) announces a new Open Access policy, representing a departure from traditional practices. This policy will cease support for individual article publishing fees, known as APCs, and mandate the use of preprints while advo...
Blog Post
September 27, 2023
The UK is, hopefully, coming out of its nadir in international development. This is marked by planned rises in development spend, an ambitious new international development white paper, a supportive Minister, and a new parliament in 2024. But before considering any proposal, future governments with ...
Blog Post
September 22, 2023
The IMF has now approved ten new loans to countries under its new Resilience and Sustainability Trust (RST), established in 2022 to provide financial support on concessional terms to countries facing long-term structural challenges arising from two key threats: climate change and pandemic preparedne...
Blog Post
September 05, 2023
Today the Africa Centers for Disease Control’s (ACDC) Health Economics Programme (HEP) has published a new policy brief on the cost-effectiveness of two COVID-19 oral antivirals (COAVs), a nirmatrelvir/ritonavir combination, developed by Pfizer and sold under the name Paxlovid, and Molnupiravir, dev...